Overview
Dupixent is approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic spontaneous urticaria (CSU) in adults and adolescents aged 12 years and older who continue to have symptoms despite treatment with H1 antihistamines. Dupixent is also known by its drug name, dupilumab.

Dupixent is an interleukin (IL)-4 receptor alpha antagonist. Scientists believe it works by blocking signaling pathways for two proteins, IL-4 and IL-13, that play a key role in allergic inflammation. By reducing this inflammation, Dupixent may help decrease the frequency and severity of hives.

How do I take it?
Prescribing information states that Dupixent is given as a subcutaneous (under the skin) injection. Adults typically receive a larger initial dose, followed by a smaller dose every two weeks. For adolescents aged 12 to 17 years, the dosage depends on body weight. Dupixent should be administered exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Dupixent in people with chronic spontaneous urticaria include injection site reactions.

Rare but serious side effects may include hypersensitivity reactions such as anaphylaxis (severe allergic reaction), urticaria (hives), rash, and angioedema (swelling, especially of the face and throat). Other serious reactions may include conjunctivitis (eye inflammation), keratitis (corneal inflammation), eosinophilic conditions (disorders involving a type of white blood cell), and worsening of psoriasis or joint symptoms. People with parasitic infections should be treated before starting Dupixent, and live vaccines should be avoided during treatment.

For more information about this treatment, visit:

Dupixent (Dupilumab) Injection, for Subcutaneous Use — Regeneron